ignocaine nebulisation in covid pneumonia

Not Applicable

Not yet recruiting

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseases

• Registration Number: CTRI/2020/11/029170
• Lead Sponsor: AIIMS Rishikesh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients with PCR documented Covid -19 infection with respiratory distress(presence of hypoxia with Spo2 <93% or radiographic evidence of pneumonia,any single organ failure,sepsis)requiring supplemental oxygenation or non-invasive mechanical ventilation.

Exclusion Criteria

1.Refusal to participate in the study

2.Known allergy to lignocaine

3.Patient requiring invasive mechanical ventilation/Septic shock

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Oxygenation improvement as measured by Spo2 and ABG <br/ ><br>2.Duration of supplemental oxygen requirement <br/ ><br>3.Decrease in the need for invasive mechanical ventilation.Timepoint: Patient is improved or getting worse to receive mechanical ventilation or death. <br/ ><br>Monitored on daily basis while on receiving study intervention <br/ ><br>till the study period <br/ ><br> <br/ ><br>the study ends after patient improvement or worsens to mechanical ventilation

Secondary Outcome Measures

Name	Time	Method
Complications related to lignocaine nebulisationTimepoint: Daily basis,till the end of study